ReviewBrain, behavior, and immunity2025
Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.
Review in Brain, behavior, and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The evidence base of interventions to treat antenatal depression: a meta-analysis of randomized controlled trials.Archives of women's mental health · 2026Pooled it
- Neurocognitive sequelae following seronegative anti-NMDA receptor encephalitis with ovarian teratoma in a pediatric patient: A six-year follow-up case report.Brain, behavior, & immunity - health · 2026Article
- Big data and psychiatry: advances, constraints and future directions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network.Molecular psychiatry · 2026Review
- Neuroinflammatory Mechanisms in Depression: From Biomarkers to Anti-Inflammatory Therapy.Brain sciences · 2026Review
- Designing Clinical Trials for an Inflammatory Subtype of Major Depressive Disorder.Biological psychiatry · 2026Article
- A novel interoceptive subfornical organ to infralimbic cortex mechanism relays airway inflammation effects on fear extinction.Journal of neuroinflammation · 2026Article
- From neuroinflammation to neural inference: computational psychiatry meets precision medicine.Schizophrenia (Heidelberg, Germany) · 2026Review
- Neuroimmune regulation of behavior: Focus on sensory circumventricular organs and associated cell circuit mechanisms.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Systemic inflammation and its associations in acute moderate-severe Traumatic Brain Injury: a cross-sectional study.Brain, behavior, & immunity - health · 2026Article
- Neuroinflammation and the Female Brain: Sex-Specific Mechanisms Underlying Mood Disorders and Stress Vulnerability.Life (Basel, Switzerland) · 2026Review
- A novel interoceptive subfornical organ to infralimbic cortex mechanism relays airway inflammation effects on fear extinction.Research square · 2026Article
- The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures.EXCLI journal · 2026Review
- Response to immune-based augmentation treatment for depression: a potential role of immunosenescence.Neuroscience applied · 2026Article
- Machine learning for immune biomarkers in severe mental illness: a systematic review.Neuroscience applied · 2026Review
- Mood and Metabolism: A Bayesian Network Analysis of Depressive Symptoms in Major Depressive Disorder and Metabolic Syndrome.Journal of personalized medicine · 2025Article
- The Clinical Relevance of Immunopsychiatric Treatment: Lessons From a Transdiagnostic Case Series on Young People.Biological psychiatry global open science · 2025Article
- Altered gut microbial diversity, composition, and metabolomic potential in patients with major depressive disorder and recent suicide attempt.Brain, behavior, & immunity - health · 2025Article
- Brain Tumors, AI and Psychiatry: Predicting Tumor-Associated Psychiatric Syndromes with Machine Learning and Biomarkers.International journal of molecular sciences · 2025Review
- Biomarkers of reproductive psychiatric disorders.The British journal of psychiatry : the journal of mental science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Despite tremendous advancements in neuroscience, there has been limited impact on patient care. Current psychiatric treatments are largely non-specific, and drug development is hindered by outdated, overinclusive diagnostic categories and a "one-size-fits-all" approach. Additionally, mechanisms underlying psychiatric illnesses and their treatments with conventional medications remain poorly understood. Precision psychiatry is a strategy that holds great promise for novel therapies targeting specific pathophysiologic mechanisms in selected patients, ultimately contributing to more effective, personalized treatments. Immunopsychiatry, which focuses on the immune system's role in psychiatric disorders, exemplifies the challenges and potential solutions for precision psychiatry. Despite understanding how inflammation contributes to psychiatric illness, results of clinical trials with anti-inflammatory drugs have been inconsistent and underwhelming. Shortcomings of these trials include a lack of focus on subgroups of patients with increased inflammation, the use of non-specific outcome variables (e.g., not specific to inflammation's impact on the brain and behavior), and failure to establish target engagement of the inflammatory response. To advance anti-inflammatory treatments, clinical trials should: 1) enrich for patients using predictive biomarkers; 2) use clinical outcome assessments that align with inflammation's effects on the brain; 3) consider novel diagnostic constructs linked to inflammation; and 4) verify target engagement. Moreover, greater attention should be paid to efforts to repurpose available anti-inflammatory drugs while awaiting development of novel treatments targeting more specific immune pathways. Taken together, a collaborative approach involving academia, industry, funding agencies, patients, payors, and policymakers is required to advance Immunopsychiatry and ultimately provide a roadmap for successful implementation of precision psychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.